Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant
Al-Saleh, Khalid A., El Zawahry, Heba Mohamed, Bounedjar, Adda, Oukkal, Mohammed, Saadeddin, Ahmed, Mahfouf, Hassen, Kamel, Bouzid, Bensalem, Assia, Abdel-Razeq, Hikmat, Kandil, Alaa, Abulkhair, Omalkhair A. M., Al-Foheidi, Meteb Owaish, Ghosn, Marwan, Boussen, Hamouda, Haddaoui, Abderrazak, Ayari, Jihene Braham, Alghamdi, Mohammed, Abdulaziz, Nashwa A., Kullab, Sharif Ahmed, Nabholtz, Jean-Marc A.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial
Al-Saleh, Khalid A, Bounedjar, Adda, Oukkal, Mohammed, Mahfouf, Hasen, Bouzid, Kamel, Bensalem, Assia, Fillali, Prof Taha, Larbaoui, Blaha, Kandil, Alaa, Alfoheidi, Meteb, Errihani, Hassan, Ghosn, Marwan, Abdulaziz, Nashwa A, Dabouz, Farida, Bahadoor, Mohun Ranvir K., El Zawahry, Heba Mohamed, Kullab, Sherif A, Nabholtz, Jean-Marc A.
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article